When vitreous haemorrhage arises from neovascularization in the setting of proliferative retinopathy, the underlying vascular proliferation driving the bleed must be addressed directly. The clinical priority is inducing regression of the abnormal new vessels responsible for the haemorrhage.
Neovascularization from proliferative retinopathy is the underlying cause. The abnormal new vessels are the source of the vitreous bleed and represent the primary therapeutic target.
Management centres on laser-based intervention directed at the retina, which can be performed even in the presence of residual haemorrhage when conditions allow. An alternative interim approach targeting the neovascular process may also be considered while definitive treatment is arranged. The complete sequence, criteria, and options are available in the full protocol.
Regression of neovascularization.